CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003-2013
Dohun Kim, So Young Kim, Beomseok Suh, Jong Hyock Park
Cancer Research and Treatment. 2018;50(3):757-767.   Published online 2017 September 4    DOI: https://doi.org/10.4143/crt.2017.050

Excel Download

Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003-2013
Cancer Research and Treatment. 2018;50(3):757-767   Crossref logo
Link1 Link2 Link3

Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003–13
Heart, Lung and Circulation. 2018;27:S563   Crossref logo
Link1 Link2

P-66 Trend of lung cancer in recent 5 years; Analysis as viewed from age, gender, pathological types, stage of disease, therapeutic modality, and prognosis
Lung Cancer. 2003;41:S107   Crossref logo
Link1 Link2

190 Tolvaptan – cost effective treatment of SIADH in malignancies
Lung Cancer. 2013;79:S66   Crossref logo
Link1 Link2

A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis
Lung Cancer. 2013;82(3):461-468   Crossref logo
Link1 Link2

47P TREATMENT OPTIONS FOR SMALL CELL LUNG CANCER: DOES LANREOTIDE REPRESENT A NEW CHOICE?
Lung Cancer. 2013;80:S20-S21   Crossref logo
Link1 Link2

Staging of lung cancer: A cost-effectiveness analysis
Lung Cancer. 1986;2(3):220   Crossref logo
Link1 Link2

Cost analysis of hospital treatment—two chemotherapic regimens for non-surgical non-small cell lung cancer
Lung Cancer. 1996;14(1):31-44   Crossref logo
Link1 Link2

O-12 The cost effectiveness (CE) and cost to medicare of gefitinib (Iressa; ZD1839) for the third-line treatment of non-small cell lung cancer (NSCLC): Can medicare afford the bill?
Lung Cancer. 2003;41:S7-S8   Crossref logo
Link1 Link2

Chemotherapy benefit and cost-effectiveness of treatment for advanced lung cancer
Lung Cancer. 1997;18:68-69   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.